208 related articles for article (PubMed ID: 28341486)
1. Polo-like kinase 1 expression is suppressed by CCAAT/enhancer-binding protein α to mediate colon carcinoma cell differentiation and apoptosis.
Dasgupta N; Thakur BK; Ta A; Das S; Banik G; Das S
Biochim Biophys Acta Gen Subj; 2017 Jul; 1861(7):1777-1787. PubMed ID: 28341486
[TBL] [Abstract][Full Text] [Related]
2. G9a stimulates CRC growth by inducing p53 Lys373 dimethylation-dependent activation of
Zhang J; Wang Y; Shen Y; He P; Ding J; Chen Y
Theranostics; 2018; 8(10):2884-2895. PubMed ID: 29774081
[No Abstract] [Full Text] [Related]
3. Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo.
Xu WJ; Zhang S; Yang Y; Zhang N; Wang W; Liu SY; Tian HW; Dai L; Xie Q; Zhao X; Wei YQ; Deng HX
Cancer Biother Radiopharm; 2011 Aug; 26(4):427-36. PubMed ID: 21797676
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of polo-like kinase 1 promotes hyperthermia sensitivity via inactivation of heat shock transcription factor 1 in human retinoblastoma cells.
Yunoki T; Tabuchi Y; Hayashi A; Kondo T
Invest Ophthalmol Vis Sci; 2013 Dec; 54(13):8353-63. PubMed ID: 24366665
[TBL] [Abstract][Full Text] [Related]
5. Biological impact of freezing Plk1 in its inactive conformation in cancer cells.
Keppner S; Proschak E; Kaufmann M; Strebhardt K; Schneider G; Spänkuch B
Cell Cycle; 2010 Feb; 9(4):761-73. PubMed ID: 20139717
[TBL] [Abstract][Full Text] [Related]
6. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR
Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological significance of Polo-like kinase 1 (PLK1) expression in human malignant glioma.
Cheng MW; Wang BC; Weng ZQ; Zhu XW
Acta Histochem; 2012 Sep; 114(5):503-9. PubMed ID: 22000864
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological and prognostic implications of polo-like kinase 1 expression in colorectal cancer: A systematic review and meta-analysis.
Ran Z; Chen W; Shang J; Li X; Nie Z; Yang J; Li N
Gene; 2019 Dec; 721():144097. PubMed ID: 31493507
[TBL] [Abstract][Full Text] [Related]
9. Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells.
Han DP; Zhu QL; Cui JT; Wang PX; Qu S; Cao QF; Zong YP; Feng B; Zheng MH; Lu AG
Med Sci Monit; 2012 Jun; 18(6):BR237-46. PubMed ID: 22648245
[TBL] [Abstract][Full Text] [Related]
10. Association of p21 with NF-YA suppresses the expression of Polo-like kinase 1 and prevents mitotic death in response to DNA damage.
Lin YC; Chen YN; Lin KF; Wang FF; Chou TY; Chen MY
Cell Death Dis; 2014 Jan; 5(1):e987. PubMed ID: 24407240
[TBL] [Abstract][Full Text] [Related]
11. SBE13 joins the family of Polo-like kinase 1 (Plk1) inhibitors.
Liu X
Cell Cycle; 2010 Feb; 9(3):445-6. PubMed ID: 20130451
[No Abstract] [Full Text] [Related]
12. Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.
Lin YC; Sun SH; Wang FF
Cell Signal; 2011 Nov; 23(11):1816-23. PubMed ID: 21726628
[TBL] [Abstract][Full Text] [Related]
13. Polo-like kinase1 (Plk1) knockdown enhances cisplatin chemosensitivity via up-regulation of p73α in p53 mutant human epidermoid squamous carcinoma cells.
Tyagi S; Bhui K; Singh R; Singh M; Raisuddin S; Shukla Y
Biochem Pharmacol; 2010 Nov; 80(9):1326-34. PubMed ID: 20655883
[TBL] [Abstract][Full Text] [Related]
14. p53-dependent repression of polo-like kinase-1 (PLK1).
McKenzie L; King S; Marcar L; Nicol S; Dias SS; Schumm K; Robertson P; Bourdon JC; Perkins N; Fuller-Pace F; Meek DW
Cell Cycle; 2010 Oct; 9(20):4200-12. PubMed ID: 20962589
[TBL] [Abstract][Full Text] [Related]
15. Polo-like kinase 1 inhibitors SBE13 and BI 2536 induce different responses in primary cells.
Eckerdt F
Cell Cycle; 2011 Apr; 10(7):1027-8. PubMed ID: 21415595
[No Abstract] [Full Text] [Related]
16. Inhibition of Polo-like kinase 1 (PLK1) triggers cell apoptosis via ROS-caused mitochondrial dysfunction in colorectal carcinoma.
Feng Y; Li T; Lin Z; Li Y; Han X; Pei X; Fu Z; Wu Q; Shao D; Li C
J Cancer Res Clin Oncol; 2023 Aug; 149(10):6883-6899. PubMed ID: 36810816
[TBL] [Abstract][Full Text] [Related]
17. [Effect of antisense RNA targeting Polo-like kinase 1 on cell cycle of lung cancer cell line A549].
Zhou Q; Bai M; Su Y
Ai Zheng; 2005 Feb; 24(2):149-54. PubMed ID: 15694023
[TBL] [Abstract][Full Text] [Related]
18. Suppression of Spleen Tyrosine Kinase (Syk) by Histone Deacetylation Promotes, Whereas BAY61-3606, a Synthetic Syk Inhibitor Abrogates Colonocyte Apoptosis by ERK Activation.
Dasgupta N; Thakur BK; Ta A; Dutta P; Das S
J Cell Biochem; 2017 Jan; 118(1):191-203. PubMed ID: 27293079
[TBL] [Abstract][Full Text] [Related]
19. Fate of primary cells at the G₁/S boundary after polo-like kinase 1 inhibition by SBE13.
Keppner S; Proschak E; Schneider G; Spänkuch B
Cell Cycle; 2011 Feb; 10(4):708-20. PubMed ID: 21301227
[TBL] [Abstract][Full Text] [Related]
20. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.
Lee C; Fotovati A; Triscott J; Chen J; Venugopal C; Singhal A; Dunham C; Kerr JM; Verreault M; Yip S; Wakimoto H; Jones C; Jayanthan A; Narendran A; Singh SK; Dunn SE
Stem Cells; 2012 Jun; 30(6):1064-75. PubMed ID: 22415968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
